Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT trial

Tools
- Tools
+ Tools

ASCOT Investigators (Including: Gupta, Ajay K., Poulter, Neil R., Dobson, Joanna, Eldridge, Sandra, Cappuccio, Francesco, Caulfield, Mark, Collier, David, Cruickshank, J. Kennedy, Sever, Peter S. and Feder, Gene). (2010) Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT trial. American Journal of Hypertension, Vol.23 (No.9). pp. 1023-1030. doi:10.1038/ajh.2010.105

Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1038/ajh.2010.105

Request Changes to record.

Abstract

BACKGROUND

Some studies suggest that blood pressure (BP)-lowering effects of commonly used antihypertensive drugs differ among ethnic groups. However, differences in the response to second-line therapy have not been studied extensively.

METHODS

In the BP-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA), BP levels of European (n = 4,368), African (203), and South-Asian-(132) origin patients on unchanged monotherapy (atenolol or amlodipine) and/or on second-line therapy (added thiazide or perindopril) were compared. Interaction between ethnicity and BP responses (defined as end BP minus start of therapy BP) to both first-and second-line therapies were assessed in regression models after accounting for age, sex, and several other potential confounders.

RESULTS

BP response to atenolol and amlodipine monotherapy differed among the three ethnic groups (interaction test P = 0.05). Among those allocated atenolol monotherapy, black patients were significantly less responsive (mean systolic BP (SBP) difference +1.7 (95% confidence interval: -1.1 to 4.6) mm Hg) compared to white patients (referent). In contrast, BP response to amlodipine monotherapy did not differ significantly by ethnic group. BP responses to the addition of second-line therapy also differed significantly by ethnic group (interaction test P = 0.004). On adding a diuretic to atenolol, BP lowering was similar among blacks and South-Asians as compared to whites (referent). However, on addition of perindopril to amlodipine, BP responses differed significantly: compared to whites (SBP difference -1.7 (-2.8 to -0.7) mm Hg), black patients had a lesser response (SBP difference 0.8 (-2.5 to 4.2) mm Hg) and South-Asians had a greater response (SBP difference -6.2 (-10.2 to -2.2) mm Hg).

CONCLUSIONS

We found important differences in BP responses among ethnic groups to both first-and second-line antihypertensive therapies.

Item Type: Journal Article
Subjects: R Medicine > RC Internal medicine
Divisions: Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016)
Faculty of Medicine > Warwick Medical School
Journal or Publication Title: American Journal of Hypertension
Publisher: Nature Publishing Group
ISSN: 0895-7061
Official Date: September 2010
Dates:
DateEvent
September 2010Published
Volume: Vol.23
Number: No.9
Number of Pages: 8
Page Range: pp. 1023-1030
DOI: 10.1038/ajh.2010.105
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Funder: Pfizer Inc., New York, NY, Servier Research Group, Paris, France, NIHR Biomedical Research Centre, St Mary's charitable trust

Data sourced from Thomson Reuters' Web of Knowledge

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us